
News|Articles|April 1, 2011
FDA Pipeline Preview, April 2011 (Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy)
Recent FDA action (through, March 2011) related to Salix, Protalix, Amyvid, indacaterol, Istodax, Mucin 1 targeting peptide GO-203-2c, Intercept plasma, Lomitapide, Liver cell therapy.
Advertisement
Complete response
Recommendations for approval
Priority review
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HaVy Ngo-Hamilton, Pharm.D. | 2026 MHE Emerging Leaders in Healthcare
2
340B reform and drug shortages are among hospital pharmacy concerns, survey finds
3
Healthcare’s workforce has a scale problem, but new model is emerging
4
Dual-target ADC shows promising PFS signal in mCRPC | ASCO 2026
5

























